What comes after semaglutide and tirzepatide?
The pipeline of obesity medications is deeper than it has ever been. Triple-agonist compounds that hit GLP-1, GIP, and glucagon receptors simultaneously are reporting placebo-adjusted weight loss in the 15–24% range — beyond what current FDA-approved options deliver. Here is what is in Phase II and III trials.
| Medication Name | Target Receptor Pathways | Current Clinical Trial Phase | Reported Placebo-Adjusted Weight Loss | Unique Clinical Distinction | Source |
|---|---|---|---|---|---|
| Retatrutide | Triple GLP-1/GIP/Glucagon receptor agonist | Phase III | 24% | Simultaneous enhancement of energy expenditure and thermogenesis via triple receptor agonism and glucagon-mediated activation. | 2, Inferred, Wikipedia Non-Approved/Investigational Drug Database |
| Cagrilintide/semaglutide (CagriSema) | DACRA (Amylin analogue) and GLP-1 receptor agonist combination | Phase III | 15.6% - 20.4% | Synergistic dual-hormone approach targeting both satiety and gastric emptying pathways; combines a dual amylin and calcitonin receptor agonist with a GLP-1 agonist. | 2, Inferred, Wikipedia Non-Approved/Investigational Drug Database |
| Survodutide | Dual GLP-1/Glucagon receptor agonist | Phase III | 14.7% - 18.7% | Increases metabolic rate through direct glucagon-mediated hepatic stimulation; focuses on energy expenditure, liver health, and fibrosis reduction. | 2, Inferred, Wikipedia Non-Approved/Investigational Drug Database |
| VK | Dual GLP-1/GIP receptor agonist | Phase III | 13.1% - 14.7% | Optimized peptide delivery designed for rapid induction of weight loss and improved gastrointestinal tolerability compared to existing dual agonists. | 2, Inferred, Wikipedia Non-Approved/Investigational Drug Database |
| Bimagrumab | Myostatin inhibitor (Activin type II receptor ActRII antagonist) | Phase II | ~5% | Promotes loss of fat mass while actively preserving or increasing lean muscle mass by inhibiting myostatin signaling. | 2, Inferred, Wikipedia Non-Approved/Investigational Drug Database |
| UBT | Triple GLP-1/GIP/Glucagon receptor agonist | Phase II | 19.7% | Investigational triple-hormone-receptor candidate demonstrating high efficacy in technical biochemical target metrics. | |
| Cagrilintide | Dual amylin and calcitonin receptor agonist (DACRA) | Not in source | 7.8% | Acts on both amylin and calcitonin receptors to potentially reduce energy intake and increase energy expenditure. |
Why the triple agonists matter
Adding glucagon agonism targets energy expenditure directly — not just appetite — which is why the numbers climb past the dual-agonist plateau. Bimagrumab takes a different path entirely: a myostatin inhibitor that preserves muscle while dropping fat.
What to do while you wait
You do not need to wait for the pipeline: approved options already work, and the best results come from pairing them with structured nutrition and follow-up. Get matched with a local provider who can discuss what is available today — and what the pipeline means for the future.